YS-ON-002
/ LakeShore Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 24, 2021
YishengBio Raises $130 Million in Series B Funding to Accelerate Pipeline Development and Commercialization
(PRNewswire)
- "YishengBio Co., Ltd...announced...the closing of a US$130 million in Series B funding round....products in clinical development include YS-ON-001 for the treatment of advanced solid tumors....PIKA YS-ON-002 for solid tumor, among others, are product candidates in preclinical and discovery stages."
Commercial • Pipeline update • Oncology
1 to 1
Of
1
Go to page
1